- Market Capitalization, $K 151,281,536
- Shares Outstanding, K 2,624,593
- Annual Sales, $ 26,617 M
- Annual Income, $ 3,196 M
- 60-Month Beta 0.56
- Price/Sales 5.60
- Price/Cash Flow 17.71
- Price/Book 10.44
|Period||Period Low||Period High||Performance|
| || |
-2.58 (-4.31%)since 06/30/21
| || |
+4.25 (+8.01%)since 04/30/21
| || |
-0.57 (-0.98%)since 07/30/20
Pfizer (PFE), Merck (MRK) and others announce Q2 results. FDA approves AbbVie's (ABBV) new antibiotic injection and expands use of Merck's Keytruda and Glaxo's Shingrix and Nucala.
Emergent's (EBS) second-quarter 2021 earnings miss estimates. Revenues also fail to meet expectations. Stock down.
AstraZeneca (AZN) surpasses second-quarter estimates for revenues while earnings meet estimates. Stock up in pre-market.
Merck (MRK) misses Q2 estimates for earnings but beats the same for sales. Stock down in pre-market.
CAMBRIDGE, Britain (AP) _ Astrazeneca PLC (AZN) on Thursday reported second-quarter profit of $550 million.
Investor focus is likely to be on the sales numbers of Merck's (MRK) blockbuster oncology medicine, Keytruda.
AstraZeneca's (AZN) second-quarter results are expected to reflect the impact of strong demand for new drugs. Investors are likely to focus on an updated guidance after Alexion acquisition.
AstraZeneca's BYDUREON BCise (exenatide extended-release), once-weekly injectable suspension has been approved in the US for the treatment of type 2 diabetes (T2D); to improve glycemic control in pediatric...
|Astrazeneca Plc ADR|
|Principal International Multi-Factor Core Index|
|Advisorshares Doubleline Value Equity ETF|
|GS Access Investment Grade Corp Bond|
|T. Rowe Price Equity Income ETF|
|FT US Equity Opportunities ETF|
|3rd Resistance Point||59.42|
|2nd Resistance Point||59.01|
|1st Resistance Point||58.32|
|1st Support Level||57.23|
|2nd Support Level||56.82|
|3rd Support Level||56.14|